CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Omalizumab (Drug Plan Submission)

Last Updated: October 6, 2015
Result type: Reports
Project Number: SR0457-000
Product Line: Reimbursement Review

Generic Name: Omalizumab (Drug Plan Submission)

Brand Name: Xolair

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Asthma, severe persistent

Indications: Asthma, severe persistent

Submission Type: Drug Plan Initiated

Project Status: Complete

Date Recommendation Issued: May 18, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions